keyword
MENU ▼
Read by QxMD icon Read
search

high risk prostate cancer

keyword
https://www.readbyqxmd.com/read/28537990/impact-of-the-primary-information-source-used-for-decision-making-on-treatment-perceptions-and-regret-in-prostate-cancer
#1
Narek Shaverdian, Amar U Kishan, Darlene Veruttipong, D Jeffrey Demanes, Patrick Kupelian, Susan McCloskey, Michael L Steinberg, Christopher R King
OBJECTIVE: To assess the impact of the primary source of information used by prostate cancer patients to select a radiation treatment on their overall treatment experience and on treatment regret. METHODS: Patients with low to favorable intermediate-risk prostate cancer treated with stereotactic body radiation therapy, intensity-modulated radiation therapy, or high-dose rate brachytherapy were surveyed. The questionnaire explored the decision-making experience, treatment experience, and treatment regret...
May 23, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28534184/evaluation-of-cardiovascular-ischemic-event-rates-in-dasatinib-treated-patients-using-standardized-incidence-ratios
#2
Giuseppe Saglio, Philipp le Coutre, Jorge Cortes, Jiří Mayer, Philip Rowlings, François-Xavier Mahon, Glenn Kroog, Kyna Gooden, Milayna Subar, Neil P Shah
With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY)...
May 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28532400/oligometastases-from-prostate-cancer-local-treatment-with-stereotactic-body-radiotherapy-sbrt
#3
Gregor Habl, Christoph Straube, Kilian Schiller, Marciana Nona Duma, Markus Oechsner, Kerstin A Kessel, Matthias Eiber, Markus Schwaiger, Hubert Kübler, Jürgen E Gschwend, Stephanie E Combs
BACKGROUND: The impact of local tumor ablative therapy in oligometastasized prostate cancer (PC) is still under debate. To gain data for this approach, we evaluated oligometastasized PC patients receiving stereotactic body radiotherapy (SBRT) to bone metastases. METHODS: In this retrospective study, 15 oligometastasized PC patients with a total of 20 bone metastases were evaluated regarding biochemical progression-free survival (PSA-PFS), time to initiation of ADT, and local control rate (LCR)...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28531226/intercenter-validation-of-a-knowledge-based-model-for-automated-planning-of-volumetric-modulated-arc-therapy-for-prostate-cancer-the-experience-of-the-german-rapidplan-consortium
#4
Carolin Schubert, Oliver Waletzko, Christian Weiss, Dirk Voelzke, Sevda Toperim, Arnd Roeser, Silvia Puccini, Marc Piroth, Christian Mehrens, Jan-Dirk Kueter, Kirsten Hierholz, Karsten Gerull, Antonella Fogliata, Andreas Block, Luca Cozzi
PURPOSE: To evaluate the performance of a model-based optimisation process for volumetric modulated arc therapy applied to prostate cancer in a multicentric cooperative group. The RapidPlan (RP) knowledge-based engine was tested for the planning of Volumetric modulated arc therapy with RapidArc on prostate cancer patients. The study was conducted in the frame of the German RapidPlan Consortium (GRC). METHODS AND MATERIALS: 43 patients from one institute of the GRC were used to build and train a RP model...
2017: PloS One
https://www.readbyqxmd.com/read/28529342/circulating-tumor-cells-and-serum-levels-of-mmp-2-mmp-9-and-vegf-as-markers-of-the-metastatic-process-in-patients-with-high-risk-of-metastatic-progression
#5
Marketa Skerenova, Veronika Mikulova, Otakar Capoun, Tomas Zima, Petra Tesarova
BACKGROUND AND AIMS: Metastases are a severe complication in cancer patients and biomarkers predicting their progression are still lacking for specific groups of patients. HER2 positive breast cancer (HER2 BC) patients on trastuzumab therapy are at risk of the development of unpredictable and often fatal central nervous system (CNS) metastases and castration resistant prostate cancer (CRPC) patients urgently need a marker of disease progression during therapy. Proposed metastatic markers: circulating tumor cells (CTC), serum levels of matrix metalloproteinase 2 (MMP-2), 9 (MMP-9) and vascular endothelial growth factor (VEGF) were prospectively studied to confirm their utility in these two narrowly defined groups of cancer patients...
May 16, 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/28528811/ability-of-a-genomic-classifier-to-predict-metastasis-and-prostate-cancer-specific-mortality-after-radiation-or-surgery-based-on-needle-biopsy-specimens
#6
Paul L Nguyen, Zaid Haddad, Ashley E Ross, Neil E Martin, Samineh Deheshi, Lucia L C Lam, Jijumon Chelliserry, Jeffrey J Tosoian, Tamara L Lotan, Daniel E Spratt, Radka S Stoyanova, Sanoj Punnen, Kaye Ong, Christine Buerki, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Kasra Yousefi, Voleak Choeurng, Elai Davicioni, Bruce J Trock, Christopher J Kane, Alan Pollack, John W Davis, Felix Y Feng, Eric A Klein
BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers...
May 18, 2017: European Urology
https://www.readbyqxmd.com/read/28528292/cancer-incidence-in-the-western-australian-mining-industry-1996-2013
#7
Nita Sodhi-Berry, Alison Reid, Lin Fritschi, Aw Bill Musk, Roel Vermeulen, Nicholas de Klerk, Susan Peters
BACKGROUND: Miners are frequently exposed to established and potential carcinogens. We aimed to assess cancer incidence in miners relative to the general population and identify high-risk subgroups. METHODS: Incident cancers in Western Australian miners (n=153,922; 86% male) during 1996-2013 were identified. Indirectly standardised incidence ratios (SIRs) were calculated and mixed-effects Poisson models were used to calculate Incidence Rate Ratios (IRRs) to identify high-risk within-cohort subgroups...
May 18, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28523407/heterogeneous-oncologic-outcomes-according-to-surgical-pathology-in-high-risk-prostate-cancer-implications-for-better-risk-stratification-and-preoperative-prediction-of-oncologic-outcomes
#8
Seung-Kwon Choi, Myungsun Shim, Myong Kim, Myungchan Park, Sangmi Lee, Cheryn Song, Hyung-Lae Lee, Hanjong Ahn
PURPOSE: To evaluate the better risk stratification based on surgical pathology, and to predict oncologic outcomes after radical prostatectomy (RP) with a better scoring system in high-risk prostate cancer (PCa) patients. METHODS: We evaluated high-risk PCa patients (PSA >20 ng/ml, ≥cT3a, or Gleason score 8-10) who underwent RP between 2007 and 2013 at our institute. We classified patients into three groups according to their pathologic outcomes: favorable (pT2, Gleason score ≤7, and node negative), intermediate (specimen-confined disease (pT2-3a, node negative PCa with negative surgical margins) but not in the favorable group), and unfavorable (the remaining patients)...
May 18, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28521474/an-%C3%AE-3-fatty-acid-desaturase-expressing-gene-attenuates-prostate-cancer-proliferation-by-cell-cycle-regulation
#9
Jinshun Pan, Sujin Zhou, Rong Xiang, Zhenggang Zhao, Shanshan Liu, Ning Ding, Sijia Gong, Yan Lin, Xiaoxi Li, Xiaoming Bai, Fanghong Li, Allan Z Zhao
Previous studies have reported that Ω-6 and Ω-3 fatty acids have opposing effects on cancer development. Consuming high levels of long-chain Ω-3 polyunsaturated fatty acids (PUFAs) has been shown to reduce prostate cancer risk and increase chemotherapy sensitivity. The sdd17 gene encodes an Ω-3 fatty acid desaturase, which converts arachidonic acid into eicosapentaenoic acid (EPA). However, little is known regarding the function of the sdd17 gene in tumor cells in vitro. In the present study, prostate cancer cells were infected with the msdd17 gene, which allowed the endogenous production of Ω-3 PUFAs...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28516190/-is-there-still-a%C3%A2-role-for-active-surveillance-in-prostate-cancer
#10
M Stöckle
Long-term data demonstrate a higher oncological risk associated with active surveillance (AS) than initially anticipated. In particular, patients with more than two tumor-involved biopsy cores and/or Gleason-7a foci must be regarded as having an increased risk of developing an incurable stage of disease after an initial attempt of AS. For patients with Gleason-7a foci, the 15-year risk of suffering from an incurable tumor stage is reported as high as 60%. Furthermore, life expectancy must be regarded as one of the major risk factors to finally develop symptomatic incurable disease...
May 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28515930/determination-of-adequate-pelvic-lymph-node-dissection-range-for-japanese-males-undergoing-radical-prostatectomy
#11
Nobuki Furubayashi, Takahito Negishi, Hidenori Iwai, Kei Nagase, Kenichi Taguchi, Mototsugu Shimokawa, Motonobu Nakamura
The present study aimed to determine the adequate pelvic lymph node dissection (PLND) range for Japanese males undergoing radical prostatectomy. A total of 467 Japanese patients who underwent antegrade radical prostatectomy at the National Kyushu Cancer Center (Fukuoka, Japan) were retrospectively reviewed. The patients were divided into two groups according to the PLND extent: The standard (obturator + internal iliac nodes) group and the expanded (standard + additional nodes) group, which accounted for 64...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28514930/hypofractionated-stereotactic-body-radiotherapy-for-localized-prostate-cancer-first-nordic-clinical-experience
#12
Kristiina Koskela, Jan-Erik Palmgren, Janne Heikkilä, Heli Virsunen, Liisa Sailas, Päivi Auvinen, Jan Seppälä, Vesa Kataja
BACKGROUND: The use of hypofractionated stereotactic body radiotherapy (SBRT) as primary treatment modality in clinically localized prostate cancer (PCa) is emerging, because the low α/β-ratio favors the use of high dose per fraction in PCa. There is a need for more data about SBRT, especially in high-risk PCa patients. The purpose of this retrospective study was to evaluate the safety and the short-term efficacy of robotic SBRT in a clinical patient cohort with localized PCa including also high-risk patients (D'Amico risk stratification)...
July 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28514929/five-year-outcomes-from-a-prospective-trial-of-image-guided-accelerated-hypofractionated-proton-therapy-for-prostate-cancer
#13
Randal H Henderson, Curtis Bryant, Bradford S Hoppe, R Charles Nichols, William M Mendenhall, Stella Flampouri, Zhong Su, Zuofeng Li, Christopher G Morris, Nancy P Mendenhall
PURPOSE: To report 5-year outcomes of a prospective trial of image-guided accelerated hypofractionated proton therapy (AHPT) for prostate cancer. PATIENTS AND METHODS: 215 prostate cancer patients accrued to a prospective institutional review board-approved trial of 70Gy(RBE) in 28 fractions for low-risk disease (n = 120) and 72.5Gy(RBE) in 29 fractions for intermediate-risk disease (n = 95). This trial excluded patients with prostate volumes of ≥60 cm(3) or International Prostate Symptom Scores (IPSS) of ≥15, patients on anticoagulants or alpha-blockers, and patients in whom dose-constraint goals for organs at risk (OAR) could not be met...
July 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28512777/the-australian-laparoscopic-radical-prostatectomy-learning-curve
#14
Marcus Handmer, Charles Chabert, Ronald Cohen, Troy Gianduzzo, Paul Kearns, Daniel Moon, Jason Ooi, Tom Shannon, David Sofield, Andrew Tan, Mark Louie-Johnsun
BACKGROUND: International estimates of the laparoscopic radical prostatectomy (LRP) learning curve extend to as many as 1000 cases, but is unknown for Fellowship-trained Australian surgeons. METHODS: Prospectively collected data from nine Australian surgeons who performed 2943 consecutive LRP cases was retrospectively reviewed. Their combined initial 100 cases (F100, n = 900) were compared to their second 100 cases (S100, n = 782) with two of nine surgeons completing fewer than 200 cases...
May 16, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28511220/-significance-and-value-of-psma-ligands-in-prostate-cancer
#15
Claudia Gasch, Stefan Körber, Christophe Kremer, Matthias Eiber, Clemens Kratochwil, Uwe Haberkorn, Markus Hohenfellner, Boris Hadaschik, Frederik L Giesel
In recent years, PSMA-targeting PET tracers such as (68)Ga-PSMA-11 have shown promising results, thus contributing to a better management of prostate cancer patients. At the present time, (68)Ga-PSMA-11 is most frequently used for diagnostic evaluation in the setting of biochemical recurrence of prostate cancer. In this context, the (68)Ga-PSMA-11 PET/CT delivers superior detection rates compared to conventional imaging, especially for the detection of small, unsuspicious lesions or lesions in the presence of low PSA values...
April 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28505899/re-urologist-level-correlation-in-the-use-of-observation-for-low-and-high-risk-prostate-cancer
#16
Samir S Taneja
No abstract text is available yet for this article.
June 2017: Journal of Urology
https://www.readbyqxmd.com/read/28504934/vision-based-surgical-field-defogging
#17
Xiongbiao Luo, A McLeod, Stephen Pautler, Christopher Schlachta, Terry Peters
Fogged surgical field visualization that is a common and potentially harmful problem can lead to inappropriate device use and incorrectly targeted tissue and increase surgical risks in endoscopic surgery. This work aims to remove fog or smoke on endoscopic video sequences to augment and maintain a direct and clear visualization of the operating field. A new visibilitydriven fusion defogging framework is proposed for surgical endoscopic video processing. This framework first recovers the visibility and enhances the contrast of hazy images...
May 11, 2017: IEEE Transactions on Medical Imaging
https://www.readbyqxmd.com/read/28503095/the-cholesterol-metabolite-27-hydroxycholesterol-stimulates-cell-proliferation-via-er%C3%AE-in-prostate-cancer-cells
#18
Shaneabbas Raza, Megan Meyer, Casey Goodyear, Kimberly D P Hammer, Bin Guo, Othman Ghribi
BACKGROUND: For every six men, one will be diagnosed with prostate cancer (PCa) in their lifetime. Estrogen receptors (ERs) are known to play a role in prostate carcinogenesis. However, it is unclear whether the estrogenic effects are mediated by estrogen receptor α (ERα) or estrogen receptor β (ERβ). Although it is speculated that ERα is associated with harmful effects on PCa, the role of ERβ in PCa is still ill-defined. The cholesterol oxidized metabolite 27-hydroxycholesterol (27-OHC) has been found to bind to ERs and act as a selective ER modulator (SERM)...
2017: Cancer Cell International
https://www.readbyqxmd.com/read/28498624/additional-benefit-of-using-a-risk-based-selection-for-prostate-biopsy-an-analysis-of-biopsy-complications-in-the-rotterdam-section-of-the-european-randomized-study-of-screening-for-prostate-cancer-erspc
#19
Peter K F Chiu, Arnout R Alberts, Lionne D F Venderbos, Chris H Bangma, Monique J Roobol
OBJECTIVE: To investigate biopsy complications and hospital admissions that could be reduced by the use of ERSPC risk calculators (RC). MATERIALS AND METHODS: All biopsies in the Rotterdam section of the ERSPC from 1993 to 2015 were included. Biopsy complications and hospital admission data were prospectively recorded in questionnaires that were completed 2 weeks after biopsy. The ERSPC RC3 and RC4 were applied to men attending the first and subsequent rounds of screening, respectively...
May 12, 2017: BJU International
https://www.readbyqxmd.com/read/28497893/the-4kscore-blood-test-accurately-identifies-men-with-aggressive-prostate-cancer-prior-to-prostate-biopsy-with-or-without-dre-information
#20
Stephen M Zappala, Yan Dong, Vincent Linder, Michael Reeve, Daniel D Sjoberg, Vinita Mathur, Richard Roberts, David Okrongly, Jay Newmark, Garnnum Sant, Mitchell Steiner
INTRODUCTION: The 4Kscore Test is a prebiopsy blood test that incorporates four prostate protein biomarkers along with patient clinical information to determine a man's risk for high-grade, aggressive (Gleason ≥7) prostate cancer. However, some men likely to benefit from the test may be seen in primary care settings where the digital rectal examination (DRE) information is not always obtained. In this study, we assessed the clinical validity of the 4Kscore Test when the DRE information was not included in the algorithm...
May 12, 2017: International Journal of Clinical Practice
keyword
keyword
69231
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"